Q-omics provides the consensus-scored LY6G5C profile across patient tissues and cancer cell-line models. LY6G5C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LY6G5C is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, LY6G5C RNA expression shows 17,257 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, KICH, and ACC as cancer lineages where LY6G5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY6G5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY6G5C survival associations across molecular data types. LY6G5C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY6G5C RNA expression–survival associations across cancer types. High LY6G5C expression shows unfavorable associations in ACC and MESO, but favorable associations in UCEC, PAAD, UVM and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LY6G5C RNA expression.
This table summarizes LY6G5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LY6G5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY6G5C shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, COAD, LIHC and STAD. The KICH box plot shows higher LY6G5C RNA expression in normal versus tumor tissue (log2 FC = −1.170, t-test p < 0.001).
This table shows molecular features associated with LY6G5C in patient tissues and cancer cell lines. In patient samples, LY6G5C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LY6G5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
